Category: Covid-19 Vaccine

Page 454«..1020..453454455456..460470..»

Gov. Wolf and COVID-19 Vaccine Task Force Announce that All Adults in Pennsylvania are Eligible Tomorrow to Schedule COVID-19 Vaccination Appointments…

April 12, 2021

Governor Tom Wolf and the COVID-19 Vaccine Task Force announced that effective tomorrow, Tuesday, April 13, all Pennsylvania adults will be eligible to schedule an appointment for the COVID -19 vaccine.

We need to maintain acceleration of the vaccine rollout, especially as case counts and hospitalization rates have increased, Gov. Wolf said. Therefore, just as President Biden has brought forward universal adult access to vaccines from May 1 to April 19, we are moving Pennsylvanias timeline of universal adult access to April 13.

The Department of Health noted that there is ongoing appointment availability in many parts of the state even as Phase 1A and B continue and 1C begins today. With the change in eligibility, those in Phase 2 will become eligible, opening up vaccines to all. Our ongoing initiative with the Area Agencies on Aging to provide assistance to vulnerable seniors for accessing vaccine will continue, as will our other equity initiatives.

Everyone needs and should be afforded the opportunity to access the vaccine as soon as possible, Acting Sec. of Health Alison Beam said. And, this change provides earlier access for many, including college students increasing the likelihood of completion of two-dose regimens prior to leaving campus for the summer. It also means simpler, streamlined operations for vaccine providers that no longer need to check eligibility of people making appointments.

To date, Pennsylvania providers have administered more than 6 million vaccines and the state is ranked among the top 20 states for first-dose vaccinations. More than 2.4 million Pennsylvanians are fully vaccinated.

Pennsylvanians can find providers on the COVID-19 Vaccine Provider Map here.

Please get vaccinated, said Sen. Art Haywood.

It is precisely the bipartisan cooperation of this Joint Task Force coupled with the tremendous work of our provider network that has allowed our Commonwealth to make rapid progress in our vaccine rollout, now expanding eligibility so that every Pennsylvanian who wants to be vaccinated has the opportunity to do so immediately, said Sen. Ryan Aument. Because we have maintained our commitment to residents within phases 1A and 1B, we can now further accelerate the rollout and protect our communities, particularly by ensuring that college students can be vaccinated before returning home to their families for the summer.

The administration, our task force, and all of our local providers have collaborated together to achieve the goal put forth by President Biden, said Rep. Bridget Kosierowski. With the number of COVID-19 positive cases continuing to rise some areas of our state, it is imperative that everyone who wants to schedule an appointment for a vaccine can have that opportunity to do so.

Im pleased we are able to speed up eligibility so that all Pennsylvanians who want a vaccine can schedule one, Rep. Tim ONeal said. Western Pennsylvania has hosted a number of vaccine clinics in recent days where supply has outstripped demand. We were able to get approval to expand eligibility at one of these clinics, but it only makes sense to open vaccinations to all. The work of the task force has shown when all parties work in a collaborative fashion, we can accomplish a lot in a short timeframe.

This further-accelerated plan will move us much closer to the goal of vaccinating Pennsylvanians as quickly and equitably as possible, Gov. Wolf said.

Here is the original post:

Gov. Wolf and COVID-19 Vaccine Task Force Announce that All Adults in Pennsylvania are Eligible Tomorrow to Schedule COVID-19 Vaccination Appointments...

Loudoun Opens COVID-19 Vaccine to All 16 and Older – Loudoun Now

April 12, 2021

The Loudoun County Health Department has announced that as of today every Loudoun resident 16 years of age and older may sign up for a COVID-19 vaccination appointment.

The expansion of vaccination opportunities earlier than expected is a result of the efficient vaccination of people who were in the Phase 1 priority groups over the past three and half months,stated Loudoun County Health Director Dr. David Goodfriend. As we begin making appointments for people in the general population, we will continue to prioritize vaccination for anyone in groups who are at greater risk of exposure and illness and for spreading the virus.

All health districts in Virginia are scheduled to advance to Phase 2 of the states vaccination plan no later than April 18.

According to the county health department, since April 1, Loudoun has vaccinated on average more than 4,100 people a day at the countys COVID-19 vaccination site at the Dulles Town Center.And, they said, their capacity is still limited by supplywith more vaccine doses, they could vaccinate more people each day.

The announcement also came after plumbing problems reportedly closed the Dulles Town Center vaccination site on Saturday, April 10, causing the vaccination appointments for that day to be canceled. According to the county, those people are being contacted to reschedule.

It also comes only a week after the county opened up vaccination appointments to Phase 1c, the last people in the Phase 1 priority group. The first Phase 1 vaccine doses began at the end of December.

Anyone under 18 receiving the vaccine must be accompanied by a parent or guardian at their vaccination appointment, or they will be turned away.

To pre-register and be put on the list for an appointment, go to vaccinate.virginia.govor call 1-877-829-4682. People seeking COVID-19 vaccination can also look for appointments at pharmacies and other locations in the region by visitingvaccinefinder.org. That is a separate sign up, since those organizations do not coordinate their registrations with the Health Department.

Even for fully vaccinated people, state and federal health officials continue to encourage COVID-19 precautions such as avoiding crowds, maintaining six feet of separation from others, frequent hand washing and wearing a mask.

Related

More here:

Loudoun Opens COVID-19 Vaccine to All 16 and Older - Loudoun Now

The Next Step in Covid-19 Vaccines May Be Through the Nose – Smithsonian Magazine

April 12, 2021

In a collective display of scientific advancement, the Covid-19 vaccines from Pfizer, Moderna and Johnson & Johnson seem to be astoundingly effective at preventing severe disease and death from Covid-19. All are intramuscular, meaning they are injected into the muscle tissue. Once the vaccine materials seep into the bloodstream, they induce the creation of antibodies, which then circulate in the blood throughout the body, protecting some of the most vital organs and creating whats called systemic immunity. This immune response protects the body from serious illness and death, but the response only builds after the virus has fully entered the body.

Their ability to protect the human body from Covid-19 illness is truly incredible, but the SARS-CoV-2 virus still has an entryway into the body left unprotected by the vaccines: the nose and mouth. Those two gateways, and their ability to transmit the virus, are what mask mandates all about. Face coverings have been shown to impede the spread of the aerosol virus, protecting their wearers and those around them from infecting each other.

But what if a new, intranasal vaccine existed?

With a spritz up the nose, such a vaccine would travel through the upper respiratory tract, encouraging the body to produce protective antibodies there. If successful, this immune response would both neutralize the virus on its way in before making a person sick, and it would ensure that no live virus escapes when they exhale, cough or sneeze. While early data on efforts to promote mucosal immunity is promising, companies are still in early-stage clinical trials and a marketable, intranasal Covid-19 vaccine may be a year out.

For real control of the pandemic, what we want to do is not just prevent serious disease and deathas good as that is in itselfbut we want to be able to break the chains of transmission, says Michael Russell, a mucosal immunologist with the University of Buffalo.

The existing vaccines achieve systemic immunity by spurring the production of antibodies called immunoglobulin G, or IgG and killer T cells. These cells and proteins are highly effective at neutralizing the virus before seriously damaging our key organs. But to prevent the virus from entering into the body in the first place, scientists likely need to target the mucosal system. The moist tissue lining the nasal and mouth are part of the mucosal system, which stretches from there all the way through the gastrointestinal and reproductive tracts. Here, a different class of antibodies exude from the mucosa to neutralize viruses and other intruders. The mucosal system secretes specialized antibodies called Immunoglobulin A or IgA. When faced with an intruding virus or bacterium, the mucosa releases IgA to neutralize it.

If a Covid-19 vaccine can create a strong mucosal immune response, the body may be better equipped to stop the virus before it makes its way to essential organs, like the heart and lungs. Plus, secretory IgA antibodies in the mouth and nose are more potent against SARS-CoV-2 than the IgG antibodies induced by intramuscular vaccines, according to a study published in Science Translational Medicine in January. Proponents of intranasal vaccines are hopeful that boosting secretory IgA in this way would be a step up from the protection offered by the existing vaccines.

For the body to create the secretory IgA antibodies necessary to neutralize incoming virus, many scientists think a vaccine needs to be applied along the natural route of infection. This means administering the vaccine through the nose via a nasal spray and letting it travel through the mucosa.

Injected Covid-19 vaccines dont appear to elicit much of an antibody response in the mucosa, says Michal Tal, an immunologist at Stanford University and team lead of the Stanford Saliva Studyan effort to track antibodies that are secreted in saliva from people who have been vaccinated. Many people who have been naturally infected with Covid-19 seem to create a mucosal immune response early in the infection, but for those relying on a vaccine to build their immunity, an intranasal vaccine may provide a necessary IgA supplement to their systemic immunity.

To protect the nose from being a site where infection can get in and infection can get back out, you really have to have IgA there, Tal says.

Globally, five intranasal vaccine candidates are currently undergoing clinical trials, according to the World Health Organization. Scot Roberts, chief scientific officer of Altimmune, the only U.S. company with an intranasal vaccine in clinical trials, is betting that such an intranasal vaccine will be the best way to stop viral transmission while also protecting the body from disease. You can only get this mucosal antibody response when you do intranasal administration, because it's a very localized immunity, he says.

Recent research indicates that the Pfizer and Moderna vaccines may reduce viral load and asymptomatic transmission. A study by the CDC published last month shows that health care workers in eight U.S. locations saw a 90 percent reduction in Covid-19 transmission rates after being fully vaccinated with one of the mRNA vaccines. Another study, by Israeli researchers and published in Nature Medicine in March, indicates that the Pfizer vaccine significantly reduced viral load 12 to 37 days after vaccinationa key indicator of diminished transmission.

Still, the current vaccines havent proven to completely block transmission. Part of the reason why, Tal says, is because transmission can stem from different parts of the respiratory tract for different individuals. Some infected individuals, vaccinated or not, may not spread the virus unless theyre in close contact with others. Tal says scientists think this kind of spread originates from virus living in the nose. But other people, who act as superspreaders, may carry and spread aerosols of highly infectious virus from the lungs or the nose or both. Intramuscular vaccines can neutralize the virus in the lungs, but without mucosal immunity conferred through an intranasal vaccine, scientists say no way likely exists to fully stop transmission from the nose.

Tal adds that she was a little surprised to learn that most of the original Covid-19 candidates under Operation Warp speed were to be administered intramuscularly, despite dealing with a mucosal pathogen. But during that point in the pandemic, when death and hospitalization rates were skyrocketing, creating a formula to prevent death was paramount.

From a public health perspective, the most important key mission is to bring down deaths and hospitalizations, Tal says. So, you want to go with an intramuscular formulation where you know you're going to get really great circulating antibodies, which intranasal may not be as optimal for.

Now that more than 175 million doses of vaccine have been distributed in the U.S., scientists are looking to do more. Blocking transmission is especially important in attempts to rein in emerging viral variants. After entering the body, genetic mutations in the virus sometimes help it become more infectious or successful at evading immune responses. When this happens, the new version of the virus replicates and eventually becomes a new variant. However, if the virus is unable to breach the mucosal and systemic immune systems, it cannot live and replicate in the nasal passages or body. And if transmission is blocked, it becomes more difficult for variants to spread through a population.

Intranasal and oral vaccines are not novel concepts. Intranasal flu vaccines like FluMist, developed by AstraZeneca, were used for decades in the U.S. In the last decade, however, they became variably effective against the circulating flu strains, causing the CDC to revoke its recommendation for their use for several years. Previous intranasal flu vaccines introduce some weakened virus and allow it to replicate in the respiratory tract to create an immune response. Roberts says his companys Covid vaccine, AdCOVID, will be safer because it introduces a larger amount of vaccine and the viral vector isnt able to replicate in the body and make someone sick.

History offers a precedent to a second wave of vaccines adding a layer of protection for public health. The initial Salk polio vaccine, for instance, was first introduced as a shot. Though it was effective at preventing illness, the shot didnt stop infection. The poliovirus mostly affects the intestines, which are lined with mucus. So, scientists, including Albert Sabin, developed an oral vaccine that, when swallowed, came in direct contact with the gut mucosa to boost the mucosal immunity and stop infection and transmission. A Covid-19 intranasal vaccine would directly affect the mucosa in the same way.

That polio story is completely analogous to what we're doing, except we're doing it in the respiratory tract, Roberts says.

One of the major remaining unknowns about an intranasal vaccine is how well it will mount a lasting immune response. Russell says that the mucosal immune must constantly contend with our microbiota and the everything we eat and inhale in ways that the rest of the body does not. Thus, its possible that the mucosal systems memory of, and response to, the virus may diminish more quickly than the systemic immune response will.

Roberts predicts AdCOVID will be available in early 2022. In regions of the world where many people have been vaccinated, it may serve as a sort of seasonal re-vaccination. Roberts says that, like the flu, Covid-19 may become a seasonal illness. For people with a systemic immune response, either from intramuscular vaccination or natural infection, the intranasal vaccine could act as a booster to support their mucosal immunity and protect against variants.

As pharmaceutical companies develop second generation vaccines and think about vaccine boosters, Tal says they have renewed opportunity to devise ways to boost mucosal immunity.

Obviously, we've got to get out of the current situation we find ourselves in, but also provide a better preparedness to deal with the virus becoming endemic in the human population, Russell adds. It seems very likely that we will not totally eliminate this virus, we're going to have to live with it forever in [the] future.

Read more here:

The Next Step in Covid-19 Vaccines May Be Through the Nose - Smithsonian Magazine

Pennsylvania The Latest To Announce Covid-19 Vaccines Opening To Everyone: Heres The Full List – Forbes

April 12, 2021

More From ForbesExpanding Originals Slate, Estrella Media Taps Ex-Univision And Telemundo Star Anglica Vale To Host New Dating Show","scope":{"topStory":{"title":"Expanding Originals Slate, Estrella Media Taps Ex-Univision And Telemundo Star Anglica Vale To Host New Dating Show","uri":"https://www.forbes.com/sites/veronicavillafane/2021/04/12/expanding-originals-slate-estrella-media-taps-ex-univision-and-telemundo-star-anglica-vale-to-host-new-dating-show/","date":{"monthDayYear":"Apr 12, 2021","hourMinute":"12:10","amPm":"pm","isEDT":true},"index":1}},"id":"r70fkn0dlmeo0"},{"textContent":"

Apr 12, 2021,11:53am EDT

Apr 12, 2021,11:48am EDT

Apr 12, 2021,11:44am EDT

Apr 12, 2021,11:39am EDT

Apr 12, 2021,11:37am EDT

Apr 12, 2021,11:37am EDT

More here:

Pennsylvania The Latest To Announce Covid-19 Vaccines Opening To Everyone: Heres The Full List - Forbes

More Colleges Say They’ll Require Students To Have COVID-19 Vaccines For Fall – NPR

April 12, 2021

Duke University in North Carolina has announced that it will require students to have a COVID-19 vaccine when they return this fall. And the list of campuses with such policies is growing.

Rutgers University in New Jersey was the first, and since then more than a dozen residential colleges have followed. The University of Notre Dame; two Ivy League universities, Brown and Cornell; and Northeastern University in Massachusetts are among those requiring the vaccine for the fall. Cleveland State University will do so for all students living on campus.

As vaccines become more widely available, it's likely that many more colleges will add their own mandates. Thirty-seven states are now vaccinating all people ages 16 and up, and by April 19, all states in the U.S. will join them.

"Vaccinations are an important tool for making the fall semester safe," says Antonio Calcado, who leads Rutgers' COVID-19 task force. "We felt that just simply encouraging would not have the same effect as a requirement."

Colleges have struggled to control outbreaks on campus. Residential campuses are social spaces where viruses can (and did) spread through dorms, off-campus housing and parties. And campuses aren't insulated from their communities; there is research to suggest that spread of the coronavirus among students led to nearby deaths in nursing homes.

"This is not new"

Colleges have long required vaccinations for infectious diseases. In a survey of about 100 four-year institutions representing all 50 states and Washington, D.C., nearly all required at least one vaccine for enrollment. The MMR vaccine, which protects against measles, mumps and rubella, was required at 87.5% of campuses surveyed.

"This is not new," explains Calcado. "We have a whole portal for uploading your vaccine history and all those types of things. So that's already in place. And actually, this one just adds another vaccine to what's in place today."

When it comes to enforcement, colleges will most often use a registration hold, barring students from signing up for classes until they have met the requirement. But at some schools, not having proof of vaccination can prevent you from living in campus housing. In some rare cases, students could face expulsion.

Colleges are not new to disease outbreaks either, and in many cases those outbreaks led to vaccination campaigns on campus. In 2015, after an outbreak of meningitis on the campus of the University of Oregon in which a freshman student died, the university set up mass vaccination sites. For that campaign, the school used adhesive bandages with the school's "O" logo to advertise the vaccine to students.

Is it legal?

"Most universities have the power to require vaccines," explains Dorit Reiss, a law professor at the UC Hastings College of the Law in San Francisco. "But it does depend on what the college can do generally on vaccines and what they've done in the past."

That's because it's not just federal law that colleges need to navigate there are also state laws and the regulatory power that certain colleges possess to make requirements more generally. This can be easier for private colleges than for public ones, though some university systems, including the University of California, have power dictated by the state constitution.

Of course these types of mandates aren't new, and their legality has been challenged and upheld for nearly a century. In 1925, a student sued the University of California saying he met all the requirements to attend the school except for having a required smallpox vaccination. The judge upheld the mandate. A 2015 law in California requiring vaccines among schoolchildren has also withstood legal challenges.

But current COVID-19 vaccines have been authorized by the Food and Drug Administration under an emergency use authorization, or EUA, which introduces a "new situation" for colleges, says Reiss. "We've never had the vaccine for the entire population authorized under EUA before." So legal arguments have a little asterisk, she says, until vaccines are officially approved by the FDA, which could come as early as this summer.

"There almost certainly are going to be legal challenges because the anti-vaccine movement is already preparing for them," says Reiss. "The main arguments will include the EUA question and the fact that these vaccines are early [in use]."

Most colleges offer some exemptions to their policies, primarily for medical or religious reasons, though Reiss says that "under previous jurisprudence, you don't have to give a religious exemption. Because a vaccine mandate is not targeted at religion, it's generally applicable."

But she adds, the U.S. Supreme Court has already signaled that it's going to be more protective of religious freedom than in the past. So, she says, this is an area of uncertainty going forward.

In December, the Equal Employment Opportunity Commission issued guidance that said no current law would prevent employers from requiring vaccines or needing proof of vaccination from their employees.

According to an issue brief from the American Council on Education, which represents colleges, "the legal right of institutions to require COVID-19 vaccination for students seems likely to be upheld as vaccine availability increases." The brief also includes alternatives to mandates, including offering students incentives to be vaccinated and making online learning options available for those who are not getting the shot.

International students

One lingering question is what to do about international students. For students in countries without vaccine availability, says Calcado of Rutgers, that's a bit easier. "We can get them vaccinated. We do it ourselves. That's not a problem." The main challenge, he adds, comes with students who have been vaccinated with something that hasn't been approved in the U.S., like the AstraZeneca vaccine, which is widely used in the United Kingdom and is the subject of concerns about health risks.

Alternatives to a mandate

Even with large portions of their student bodies vaccinated, campuses are likely to keep many of the elements that have come to define COVID-19 college: masking, frequent coronavirus testing and social distancing. Even with a vaccination requirement for the fall, Rutgers has said it will continue to test all students and faculty members until public health officials advise otherwise.

The University of California San Diego plans to have campus student housing back at 100% capacity by its fall quarter. Students without the vaccine will be required to continue weekly asymptomatic testing, currently the norm on campus. Students and faculty members who are fully vaccinated in the fall will not be required to complete this testing, though wastewater testing for the virus will continue.

"I often refer to these as soft mandates," explains Reiss, who studies vaccine requirements at colleges. "You can choose not to vaccinate, but there are going to be some consequences. That incentivizes vaccination."

Getting current students vaccinated

As vaccine eligibility has opened up to include college-age adults, campuses have become vaccination sites. In an interview on WBEZ's Reset, Robert Jones, chancellor at the University of Illinois at Urbana-Champaign, says there is an "ongoing discussion" about vaccine requirements.

In the meantime, he said, the university is focused on getting the vaccine to current students. "The important thing for us, at this university and across the whole University of Illinois system, is to make sure that we get all of our students vaccinated before they depart at the end of this semester."

Other campuses are restricted by current eligibility rules. Out-of-state students in Vermont, who represent a majority of enrollment at the University of Vermont, are not able to be vaccinated until April 30. New Hampshire will expand eligibility to out-of-state residents, including college students, starting April 19.

In addition to becoming a distribution site for the vaccine, Rutgers University will also begin a mass communication campaign to educate the student body and the surrounding community about the importance of getting a COVID-19 vaccine.

"We're having students do videos," says Calcado. Administrators are working with the university's student government to design messages that resonate. "We need to take out the noise and concentrate on what the science says. The message is: What are the facts? What do we know?"

Calcado says it's not just current or prospective students he has in mind for this. "When our students go back to their communities, to their families," he says, "you know they're armed with good information."

See the article here:

More Colleges Say They'll Require Students To Have COVID-19 Vaccines For Fall - NPR

Adverse reactions to Johnson & Johnsons COVID-19 vaccine: What you need to know – WPXI Pittsburgh

April 12, 2021

PITTSBURGH There has been some concern over possible side effects from the one-shot Johnson & Johnson COVID-19 vaccine.

People previously on the fence about getting vaccinated are now more worried, as news of some people having adverse reactions to the shot came out over the past few days.

[Here is how to stay informed about coronavirus updates from WPXI]

Georgia became the third state in a week to temporarily shut down a vaccine clinic after eight people there had bad reactions to the shot. Last week, 18 people in North Carolina reported side effects -- while 11 people in Colorado had symptoms ranging from dizziness, nausea and fainting.

But one local doctor told Channel 11 the Johnson & Johnson vaccine is very safe -- and one that he highly recommends.

What these reactions appear to be are mainly fainting-type reactions, which is not an uncommon reaction to have after a vaccination, said Dr. Amesh Adalja, infectious disease specialist at Johns Hopkins University. These clinics and these batches of vaccines have already been investigated by the CDC and not found to be unsafe in any way.

Adalja said the side effect level is very low, and that is the reason people are made to sit 15-30 minutes after getting the shot -- to make sure they are okay.

Allegheny Health Network is still taking appointments for its vaccine clinic this week at Next Tier Connect in Monroeville. Everyone through Phase 1C is eligible to book an appointment.

By and large, everybody does fine with the Johnson & Johnson vaccine and there is no link to what happened in these clinics and the Johnson & Johnson vaccine, Adalja said.

As of right now, most of those sites across the U.S. are back open and offering the J&J vaccine.

Read the original post:

Adverse reactions to Johnson & Johnsons COVID-19 vaccine: What you need to know - WPXI Pittsburgh

Greece to receive first 33,600 doses of J&J COVID-19 vaccine this week – Reuters

April 12, 2021

FILE PHOTO: Vials with a sticker reading, "COVID-19 / Coronavirus vaccine / Injection only" and a medical syringe are seen in front of a displayed Johnson & Johnson logo in this illustration taken October 31, 2020. REUTERS/Dado Ruvic

ATHENS (Reuters) - Greece will get a first tranche of the single-dose Johnson & Johnson vaccine against COVID-19 on Wednesday and will start inoculating people with it next week, a senior health ministry official said on Monday.

The Greek statement came as the U.S. company began delivering its vaccine to countries across the EU, a few days later than initially planned due to production issues.

We will receive the first 33,600 doses of the single-dose vaccine by Johnson & Johnson on Wednesday, April 14, the countrys secretary general in charge of vaccinations, Marios Themistocleous, told a weekly briefing.

Greece has inoculated more than 2 million of its 11 million population with at least one shot of the Pfizer, AstraZeneca or Moderna vaccines.

Along with new deliveries from those companies, Greece has said it expects 1.3 million doses of the Johnson & Johnson vaccine by June.

The country has fared better than other EU countries in the first wave of the pandemic but has imposed strict restrictions since November to deal with a resurgence of infections and ramped up vaccinations only recently.

Last week, it began distributing hundreds of thousands of free home testing kits to senior high school students and their teachers before they resume in-class lessons on Monday.

Greece, which had emerged from a multi-year recession before the pandemic broke out, is keen to reopen its tourism and other key sectors of its economy before the summer season.

Authorities plan to offer free self-testing kits to some 900,000 workers in retail, restaurants, transport, banks and justice this week, government spokeswoman Aristotelia Peloni said on Monday.

Reporting by Angeliki Koutantou; Editing by David Holmes

Continued here:

Greece to receive first 33,600 doses of J&J COVID-19 vaccine this week - Reuters

Terrifying Viral Videos of Shaking After COVID-19 Vaccines Are Not What They Seem – ScienceAlert

April 12, 2021

The footage is concerning, even alarming. In a number of videos posted online and already viewed millions of times on social media, two separate American women appear to experience bouts of tremors and involuntary body movements.

There is no direct connection between the women, except both had received COVID-19 vaccines shortly before their symptoms appeared, a fact some have linked to the appearance of these tremors.But scientists say there is another valid explanation for what we see in the footage.

While there's absolutely no suggestion that anyone is faking these symptoms, researchers think it's not the contents of the COVID-19 vaccines causing the shaking and convulsions.

Instead, it's possible that these viral videos depict a rare and little-understood medical condition called functional neurological disorder (FND) a neuropsychiatric disorder thought to be triggered by a range of stimuli, including physical or emotional events, injuries, medical procedures, and sometimes even the act of getting a needle injected.

"Some people with FND have a heightened awareness of their body and increased state of arousal and threat, which may hijack normal neural networks controlling voluntary movements," says neurologist David Perez from Massachusetts General Hospital (MGH).

"FND teaches us quite a bit about the complexities of the human brain."

Functional neurological disorder, sometimes also known as conversion disorder, can't definitively be diagnosed from watching videos, but nonetheless the kinds of body control issues seen limb weakness, gait problems, jerky movements, tremor, and facial spasms are all symptoms of FND.

For that reason, the US-based FND Society issued a press release in January shortly after the videos began garnering attention on social media, observing that the clinical features of FND were a match for what appeared in the footage.

"We would expect FND to develop in some individuals after vaccination due to a combination of heightened stress owing to the pandemic, feelings of uncertainty about the vaccine and the normal transient physical symptoms, and discomfort after vaccination," the FND Society wrote.

Now, to make a similar kind of point and to help boost public understanding of FND, Perez and his co-authors have penned a new commentary in JAMA Neurology, observing that the videos do look like potential episodes of FND, which if true could have been triggered by the vaccine injections, but probably not by the vaccines themselves.

"Precipitating factors, while proximal to the development of the symptoms, are not directly caused by the substances in the vaccine in the same manner that, for example, Neisseria meningitidis is the cause of meningitis," the researchers explain.

"Instead, factors such as expectations, beliefs, heightened bodily attention, arousal, and threat/emotional processing play important mechanistic roles in the pathophysiology of FND."

It's a particularly important theme right now, the researchers urge, because videos like this sometimes attract thousands of views, and may also be shared by those who advocate for conspiracy theories and anti-vaccination beliefs.

In the face of a modern health crisis like COVID-19, it's important to get the word out on the strong possibility that these videos actually show rare instances of FND.

"The spread of these videos could fuel vaccine hesitancy by giving an overly simplistic impression of potential links between the vaccine and major neurological symptoms," says Perez.

"Instead, these are symptoms of a real, brain-based disorder that sits at the intersection of neurology and psychiatry."

So far, US federal health authorities such as the CDC haven't had much to say about FND's potential role in videos like this, mainly emphasizing that side effects to COVID-19 vaccinations tend to be "mild and moderate and go away quickly".

That's an important clarification the public needs to hear, but it doesn't go far enough in terms of educating people on what FND really is, the researchers say, especially when viral videos of scary-looking shaking symptoms are scoring millions of views uploaded by people who are claiming the vaccines are directly responsible.

"A lack of direct messaging may be falsely perceived by the public that the Centers for Disease Control and Prevention is not properly surveilling adverse symptoms or, even worse, concealing them," the researchers explain.

"We must explain transparently and non-judgmentally the nature of FND, including that these symptoms are real but not the direct result of toxic vaccine effects."

The findings are reported in JAMA Neurology.

Here is the original post:

Terrifying Viral Videos of Shaking After COVID-19 Vaccines Are Not What They Seem - ScienceAlert

We could soon have vaccines for cancer and HIV thanks to COVID-19 vaccine discovery: report – Insider

April 12, 2021

Scientists are experimenting with COVID-19 vaccine technology as a way to treat terminal illnesses like cancer and HIV, Inverse reported.

That's because the coronavirus pandemic pushed scientists to create a first-of-its-kind vaccine using mRNA, or a small piece of a coronavirus particle's spike protein, to create an immune system response that protects from infection.

It's an approach vaccine researchers have been studying for the past 25 years, Insider previously reported.

Following effective clinical trial results and millions of successful vaccinations with mRNA-based COVID-19 vaccines, researchers now are looking into how the discovery could make way for other coveted treatments.

Scientists at The University of Texas MD Anderson Cancer Center are preparing to study mRNA as a cancer treatment right now.

They believe mRNA could be used to prevent cancer recurrence, Dr. Van Morris, an oncologist heading the clinical trial, said in a recent article on the MD Anderson website.

The likelihood of cancer recurring varies based on the type of cancer, and is most common with ovarian cancer, bladder cancer, and glioblastoma. Recurrence happens when small amounts of cancer cells stay in the body after treatment, multiply, and in some cases move to other areas of the body.

In the trial, which is currently in its second phase, doctors test cancer patients who had tumors removed and went through chemotherapy. Once tests reveal cancer cells that are still circulating throughout their bodies, the researchers create individualized mRNA cocktails.

"We're hopeful that with the personalized vaccine, we're priming the immune system to go after the residual tumor cells, clear them out and cure the patient," said Morris.

Scientists at Scripps University in California are also looking at HIV, a sexually transmitted infection that affects 1.2 million people worldwide, as a candidate for an mRNA vaccine.

Similar to the way the COVID-19 vaccine attaches to spiky coronavirus proteins and kills them, the HIV vaccine could do the same with HIV particles, William Schief, an immunologist at Scripps Research who helped develop the HIV vaccine in a Phase 1 trial, said in a press release.

Now that Schief's team knows mRNA can be used to target and kill HIV, they'll use that technology in future studies in the hopes of soon creating an HIV vaccine.

Since the advent of the COVID-19 vaccine, researchers have also pivoted to diseases they anticipate will become greater threats in the coming years.

The Oxford University scientists who collaborated with AstraZeneca to develop their COVID-19 vaccine are now working on a vaccine to treat the sexually transmitted disease gonorrhea, Insider previously reported.

Read more here:

We could soon have vaccines for cancer and HIV thanks to COVID-19 vaccine discovery: report - Insider

Page 454«..1020..453454455456..460470..»